H.C. Wainwright Initiates Coverage on Vascular Biogenics Ltd(NASDAQ:VBLT). The shares have been rated Buy. The rating by H.C. Wainwright was issued on Jun 28, 2016.
Vascular Biogenics Ltd (VBLT) shares turned negative on Fridays trading session with the shares closing down -0.21 points or -4.56% at a volume of 8,31,239. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $4.86. The peak price level was also seen at $4.86 while the days lowest was $4.34. Finally the shares closed at $4.4. The 52-week high of the shares is $12.25 while the 52-week low is $2.76. According to the latest information available, the market cap of the company is $99 M.
Vascular Biogenics Ltd(VBLT) last announced its earnings results on May 13, 2016 for Fiscal Year 2016 and Q1.Earnings per share were $-0.21. Analysts had estimated an EPS of $-0.21.
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery development and commercialization of first-in-class treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. The Company is developing VB-111 the lead oncology product candidate from its VTS platform technology which is a gene-based biologic for the treatment of solid tumor indications with clinical programs in recurrent glioblastoma (rGBM) thyroid cancer and ovarian cancer. The Company is also conducting a program targeting anti-inflammatory diseases based on the use of its Lecinoxoid platform technology. Lecinoxoids are a class of small molecules developed by the Company that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation.